Archive | December, 2016

2016 Highlights: A Look Back at Next Phase’s Top 10 Articles

29 Dec

By Lucy Parkinson, Director of Research, LSN

Throughout 2016, Next Phase has brought you updates and advice on early stage life science fundraising. This week, we’d like to take a look back at the highlights of the year, from some hard data on drug development funding to tips on marketing and pitching your company. We hope you enjoy this roundup of our top 10 articles of the year. See you in 2017.

  1. Drug Development: What Does It Cost, and Who Has The Capital?
  2. The Journey of the Executive Summary and the PowerPoint Pitch Deck
  3. It’s a Numbers Game: Why Some Folks Book Lots of Partnering Meetings and Others Don’t
  4. Is the Early Stage Opportunistic Investment Strategy Broken?
  5. Top Takeaways for Pitching from the WIB, JLABS, and J&J Innovation Lobster Pot
  6. Short-Term Investors in Long-Long Development: Matching an Investor’s Time Horizon
  7. Calling All Capital Raising CEOs
  8. Corporate Partnerships On The Rise: The Toronto Opportunity
  9. How Massachusetts Wins the War for Global Talent
  10. R&D Tax Credits: A New Non-Dilutive Funding Source For Startups

Compelling New Technology Startups Selected RESI@JPM Innovation Challenge

29 Dec

By Dennis Ford, Founder & CEO, LSN

The 11th Redefining Early Stage Investments (RESI) Conference will be joining the JPM fray for our largest event yet on January 10th in San Francisco. We’re excited to announce the early stage life science companies that will be participating in the RESI Innovation Challenge.

The 30 participating companies have been hand-selected by LSN’s scientific review committee based on the innovative nature of their core technology and how well-positioned each is to capitalize on their respective market opportunities.

Digital Health


Medtech Devices

RESI San Francisco Panel Announcement: Tech Giants in Healthcare

29 Dec

By Michael Quigley, VP of Market Research, LSN


Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.

Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:

  • Iana Dimkova, Senior Associate, Healthcare, GE Ventures
  • Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
  • Rich Wilmot, Head of Corporate Venturing, Philips
  • Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS

In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.

Hot Investor Mandate 1: Asia Evergreen Fund Seeks Medtech and Biotech with Proof of Concept Data

29 Dec

A healthcare-focused US$100 million evergreen fund based in Taipei, Taiwan seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$0.5 to 2 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from Taiwan, the US, and Canada.

Within healthcare, the firm considers broadly across the healthcare field, including biomedicine, medical devices, diagnostics, and healthcare IT. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. The firm does not require board representation after investment. As a financially-driven investor, the firm does not typically request regional rights, but it can provide assistance with finding local partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 2: Midwest Pharma Looking for Early Stage Partners in Inflammation, Cardiovascular and Oncology

29 Dec

A pharmaceutical company based in the Midwest is seeking early to mid-stage technology for equity, in-licensing, and acquisition opportunities, and typically invests $5M to $50M per project depending on the opportunity. In the past two years the company also acquired two US companies at $200-300M range. The company is seeking opportunities on a global level.

The firm is interested in early to mid-stage therapeutics in inflammatory diseases, cardiovascular diseases, diabetes, and cancer. The firm seeks preclinical to clinical stage pharmaceuticals with particular interest in large molecule biologics including naturally derived molecules and fermentation based products.

SPL has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 3: Institutional Fund Manager Invests in Early and Growth Stage Healthcare Innovations for China Market

29 Dec

A professional investment institution based in Shanghai invests in early and growth stage companies in the field of biomedicine through its fund management company. The firm currently manages its $100 million fund that is set to close in 2017Q1. Typical equity investments range from US$0.5 to 4 million in Angel to Series B rounds. The firm is currently seeking opportunities from China, the US and Canada.

The firm’s key areas of focus include medicine, medical devices, diagnostics, biotechnology and healthcare services. The firm is seeking products that have large market potential in China and have achieved prototype and clinical proof-of-concept. The firm is agnostic when it comes to indication areas.

The firm is looking for competent management teams with validated assets. The firm can assist with finding registration and distribution partners in China and may request regional rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate 4: Corporate VC Seeks Diagnostics and Monitoring Devices

29 Dec

A corporate venture capital group with offices in Germany, Israel and the US makes investment with a focus on financial returns as well as bringing strategic value to its parent company.  The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of it’s second fund of €150M with a total of €350M AUM, and makes 4-6 investments per year. The firm focuses on North American, European and Israeli companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection, a connected blood glucose monitor and an enhanced PCR technology (laser PCR). The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email